Aclaris Therapeutics, Inc. (ACRS)
Stock Price:
$3.95 USD
-0.35 (-8.14%)
Updated Oct 26, 2020 1:02 PM EDT - Market open
Key Info
| Market Cap |
168.76M |
| Revenue (ttm) |
5.53M |
| Net Income (ttm) |
-101.10M |
| Shares Out |
42.72M |
| EPS (ttm) |
-2.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$3.95 |
| Previous Close |
$4.30 |
| Change ($) |
-0.35 |
| Change (%) |
-8.14% |
| Day's Open |
4.30 |
| Day's Range |
3.92 - 4.34 |
| Day's Volume |
167,647 |
| 52-Week Range |
0.70 - 5.04 |
More Stats
| Market Cap |
168.76M |
| Enterprise Value |
111.82M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.72M |
| Float |
32.71M |
| EPS (basic) |
-2.43 |
| EPS (diluted) |
-2.43 |
| FCF / Share |
-1.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
691,504 |
| Short Ratio |
2.86 |
| Short % of Float |
2.11% |
| Beta |
1.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
30.51 |
| PB Ratio |
3.69 |
| Revenue |
5.53M |
| Operating Income |
-67.30M |
| Net Income |
-101.10M |
| Free Cash Flow |
-62.60M |
| Net Cash |
56.93M |
| Net Cash / Share |
1.33 |
| Gross Margin |
-1,150.08% |
| Operating Margin |
-1,216.85% |
| Profit Margin |
-1,827.80% |
| FCF Margin |
-1,131.87% |
| ROA |
-26.70% |
| ROE |
-74.47% |
| ROIC |
-189.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.50*
(13.92% upside)
Low
3.50
Current: $3.95
High
5.00
Target: 4.50
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 4.23 | 6.15 | 1.68 | - | - | - | - |
| Revenue Growth | -31.28% | 265.48% | - | - | - | - | - |
| Gross Profit | 0.17 | 1.82 | 0.48 | - | - | - | - |
| Operating Income | -111 | -84.78 | -54.36 | -48.57 | -20.67 | -8.53 | -5.26 |
| Net Income | -161 | -133 | -68.52 | -48.08 | -20.56 | -8.52 | -5.24 |
| Shares Outstanding | 41.32 | 32.91 | 28.10 | 21.42 | 6.11 | 1.72 | 1.08 |
| Earnings Per Share | -3.90 | -4.03 | -2.44 | -2.25 | -3.79 | -6.15 | -6.45 |
| Operating Cash Flow | -96.45 | -101 | -54.66 | -34.60 | -20.37 | -7.64 | -4.92 |
| Capital Expenditures | -1.61 | -1.36 | -1.24 | -0.23 | -0.51 | -0.42 | - |
| Free Cash Flow | -98.06 | -102 | -55.90 | -34.84 | -20.88 | -8.05 | -4.92 |
| Cash & Equivalents | 75.02 | 168 | 194 | 137 | 84.87 | 16.13 | - |
| Total Debt | 0.64 | 30.06 | - | - | - | - | - |
| Net Cash / Debt | 74.38 | 138 | 194 | 137 | 84.87 | 16.13 | - |
| Assets | 98.30 | 276 | 244 | 176 | 94.08 | 17.38 | - |
| Liabilities | 28.39 | 60.44 | 18.25 | 6.60 | 1.56 | 1.46 | - |
| Book Value | 69.91 | 215 | 225 | 169 | 92.52 | -20.76 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aclaris Therapeutics, Inc. |
| Country |
United States |
| Employees |
75 |
| CEO |
Neal S. Walker |
Stock Information
| Ticker Symbol |
ACRS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ACRS |
| IPO Date |
October 7, 2015 |
Description
Aclaris Therapeutics, a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.